Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oncosec shelf filed and looks like more dilution will be coming before any positive news. The shareholder meeting postponed a few weeks looks like a red flag to me.
I just checked them out, they were the book runners for the most recent $11 mil offering a few months ago....trying to put some faith in it of course. https://www.prnewswire.com/news-releases/oncosec-medical-incorporated-announces-closing-of-11-0-million-public-offering-and-terminates-atm-and-other-financing-facility-300857172.html
I hate to say it Jeff but this new buy rating from a new analyst will probably have the market thinking Alliance Global Partner will be the book runner in Oncosec's next stock offering.
Very significant patent news for Oncosec this morning. Waiting for volume to come in and move the stock up....should happen soon.
I believe Alpha Holdings is thinking longer-term so they are not deterred by the dilution. They want to own Oncosec in the end. They may be looking to create a biotech holdings company (which may be private in California)...Alpha USA with Gargosky consulting. Snippets from pr's on Alpha website leads me to believe this. Maybe Alpha Holdings will try to negotiate a takeover with Oncosec management at a much higher price than we are seeing right now.
There is also the possibility that Oncosec may decide to take the company private with Alpha Holdings interest so high right now. If that were to happen we see a premium to current market price....but not a sky-high valuation like we had hoped. Alpha buying more shares at low $2 signals that want more. I am sure Alpha Holdings would be interested in taking Oncosec off the market if they are planning bigger things.....we will see.
We are all in the same boat. Nasdaq listing in 2015 did not attract the Big Institutions into Oncosec stock like I thought it would. Hanging on for SITC data Nov. 2018 proved to be the wrong move as the data underwhelmed the market. So here we are waiting for PISCES approval and hopes for greater interest with car-t program and also the next-gen platform of TAVO and VLA for deeper tumor indications. All very exciting stuff of course, the science is very good but money is the issue. Partnering for car-t with cash via a licensing deal with Big Pharma or Big Biotech would do the trick here. It is very possible. The fact that Oncosec sent out the proxyvote this morning should at least let investors know Oncosec is giving them plenty of time to think and vote on the two proposals and not trying to get this vote passed in a sneeky was last minute.
Even if the proposals pass I would like to think Oncosec would not issue any more shares near-term. They are signaling good things soon regarding car-t program. I would like to see something regarding concrete partnering with upfront cash soon. Could be on the horizon very soon. 3 upcoming presentations for Oncosec....1 each of the next three months....so hopefully we see a turnaround.
PROXYVOTE for Oncosec sent via e-mail this morning. I voted NO to both proposals. Meeting is August 22nd. Let's hope Oncosec announces some exciting news before then or at the meeting to justify these proposals if they pass.
Oncosec should move right back to $5 with all the recent positive news and future potential. Alpha Holdings knows it.
Totally agree with that Jeff.
I see some day traders on boards who usually move into Oncosec stock when it is ready to run....daytraders that are actually successful trading Oncosec....not like the rest of us long holders. Things turning around soon for the better.
Oncosec looks primed to make a strong move up now. The shareholder meeting is not until August 22nd....so there will be no increase in allowable shares or passing of blank check preferred shares at least until after the meeting. In the meantime Oncosec is a low-float stock with around 43% insider and tute owning it right now. Alpha Holdings taking a bit more....soemthing happening soon for sure.
AlphaBiolabs (Alpha Holdings subsidiary) Director just bought 90,000 open market shares of Oncosec.
Oncosec has updated the PISCES recruitment centers list today, july 16th. New centers in different locations have opened as they recruit new patients. Total sites are listed at 22. https://clinicaltrials.gov/ct2/show/study/NCT03132675?show_locs=Y#locn
I am going to go with a vote of NO on both shareholder proposals. I think that TNBC data in December and potential revenues from the Emerge collaboration should organically move the stock price up. If it cannot do that then Oncosec will again raise capital end of year and we will be diluted again. At this point current shareholders are sitting on massive loses. I want to see management get the stock higher without the possibility of dilution weighing over the great science this company has. I am a strong believer in the science but the market only cares about the possibility of dilution. Oncosec needs to get a licensing deal ASAP with upfront cash.....candy coating the proxy statement and saying they are on the brink of major partnerships does not hold water if it is 12 to 18 months....we have heard this before....Show Me The Money first!
Jeff, all the recent collaboration announcements Oncosec has made are a strong sign of interest in their Next-Gen platform of TAVO. The market was not so excited about PISCES interim data even though a 20% BORR will likely get them an accelerated approval early 2020. While they wait for it Oncosec is focusing on establishing pre-clinical work and jump-starting the Next-Gen platform...which will likely produce much better results than the current platform. TNBC data in December will likely be the next catalyst for the stock unless something unexected happens sooner. Upfront cash licensing deal is what we should hope for....but 2020 for something major is probably what we have to wait for.
Would be nice to see some price target upgrades for Oncosec on todays collaboration news. This is totally unexpected positive news. Any financial estimates could bring a huge boost to the share price. Let's hope. The market treats Oncosec like a lepper.
I think Alpha Holdings was the reason for the recent equity raise at lower pricing than the market was expecting. They are the largest holders of Oncosec stock. This may have been to appease them. Nothing has changed with the science. PISCES is very likely to get an approval next year and TNBC is off to a good start. Data in December for TNBC and a preliminary update on the Head and Neck trial will be coming. No more equity raises this year means the stock is ready to start moving back up again.
How I read this is that Oncosec is on the final stretch for PISCES approval into next year and if they get it....EXIT TIME.....no need for more equity financing because Merck is taking over.....and Alpha Holdings just added maximum shares plus warrants because they know this. If PISCES works everybody wins.
I think this is a very good sign that Alpha Holdings has added to their stake on the offering after the r/s. They have a seat on the board at Oncosec so they fully are aware of what is happening. If they dumped their holdings I would be very concerned. I plan on holding this through an approval next year. TNBC data in December should have deeper response rates at 6 months and so far the 3 month data is a good start. Like the initial PISCES data the market is not impressed but the therapy takes some time to really work it's magic. I guess Alpha Holdings is going to have patience with this as well as the rest of us.
warrants are at a higher price than the offering and Oncosec does not expect them to be executed until there is a market for them so I don't expect this to be dilution until we have another runup into TNBC data at the SAABS conference in December. If that shows significant response rates at 6 months evaluation time than I expect the shares to be much higher. Now consensus price targets are $20 for ONCS.
Oncosec is now trading way below book value with around $30 million in cash.
After 10 days pass Oncosec can announce they have regained Nasdaq comliance and the stock will recover. Similar to PISCES data, TNBC is showing early signs that the therapy is working at 3 months. At 6 months I would expect deeper responses and some complete responders.
I agree, this is positive. TNBC is a tough nut to crack and 20% response rates beats Keytruda monotherapy with 5%. Merck was the one who showed interest in TNBC combo therapy with Oncosec. PISCES can get an accelerated approval with a 20% BORR....and so can TNBC here in combo therapy. Merck will definitely be interested in Oncosec for these indications.
Also regarding the PISCES trial, Oncosec will not be doing updates on it because the market is underwhelmed by 24% BORR even though that is above the bar for an accelerated approval (maybe they will change their minds and update if results are above the expected current BORR). The fireworks will happen out of the blue when they announce an approval for PISCES ...but I do expect fireworks from TNBC news soon.
In the Oncosec TNBC pilot study 2 patients had a robust response when a checkpoint was added to their therapy. 1 patient relapsed but the other patient did not. So out of 2 patients, ONCS had a 50% response rate. This was exciting enough to get Merck to agree to a second keynote study with Oncosec. Preliminary data for the Phase II study now in progress will be out soon. It is a strong catalyst for the stock.
Oncosec previously showed TNBC response in the pilot study with patients treated with a checkpoint....bodes well for the combo study with Merck. Ggood results upcoming and that would be enough to get Merck thinking hard about a buyout.....they need something in TNBC to work out.
What is encouraging is that Oncosec results in IL-12 TAVO therapy with Keytruda has gained credible interest. Things are moving forward. TNBC combo data will be an eye-opener...Merck needs something to work in TNBC.
I would think "Granted" means there was no payment. Oncosec would pay royalties to Gaeta Therapeutics when therapies are commercialized and revenues are coming in.
you can't even post a positive message on this board because it is always met with an attack. Oncosec data is likely to be very good for their TNBC combo when they release it later this year. PISCES is likely to get the accelerated approval next year. Holding tight for the inevitable fireworks to happen.
Oncosec is a totally different story that Advaxis. TNBC preliminary data soon could really move ONCS stock back up quickly. Avoid the negative noise here. Oncosec is completely oversold and ready to bounce back.
I missed the ADXS run. Truly amazing period for them. Too bad it was derailed. Some may think Dan O' Connor is suspect bringing his old team associates from Advaxis and ImClone (which was sold to Eli Lilly) to Oncosec, but he is simply trying to commercialize Oncosec's TAVO platform. He has a good shot and I don't want to miss the boat here. It has been a rough ride but the science is solid and the prospects are extremely good. In the near-term I am eyeing sec filings for quarterly tute holdings in the next few weeks.
Advaxis made a series of equity offerings at much higher prices. They had a very strong run similar to Viking run last year. Clinical holds killed ADXS stock. I simply think that when Oncosec gets that accelerated approval the stars are lined up for them to go on a very strong run similar to what Advaxis already experienced....Oncosec's turn is coming soon. PISCES, TNBC, VLA platform....Head and Neck trial start....Cervical trial start......2020 will be a huge year for Oncosec. I am holding tight with my position in Oncosec.
Oncosec will apply for a second 6 month period to regain compliance. They will likely authorize a r/s because it is required to be prepared to do it....doesn't mean they will actually do one. They are well capitalized and have no debt. Also the share price slide was not intentional dilution on the part of Oncosec. If they get the 6 month extension I am positive TNBC positive data will propell the stock above $1.
Dan O'Connor left Advaxis because they were a sinking ship and the future prospects are better at Oncosec. The market will realize this soon enough.
Oncosec's Trifecta triplet trial will be an IST and have minimal cost to them. The Cervical study will fall under the GOG Foundation network-likely no cost to Oncosec. PISCES and TNBC are the two trials Oncosec needs to fund at present. NIce to see the Head and Neck trial kicking off. Soon we should get an update about the Cervical study starting.
Jeff, Oncosec just released an updated pr to address the typo. They do listen to investors.
They made an obvious typo and deleted the pr. I see a real communication disconnect. Maybe the pr team is to blame. Oncosec needs to update their investor pipeline presentation to mimic their website info and pipeline charts to convey the most up-to-date details about trials and all other information. Details are important. They were also going to do an IST with TAVO and Opdivo in melanoma and now no mention of it but it is still listed in the pipeline on the website but not the investor presentation.
Jeff, the Twitter PR with the typo was removed which did say "funded by Oncosec". Their website pr says minial cost to Oncosec.....which is what I would assume. The cervical trial will be sponsored by Oncosec when that starts though....so ONCS will remain under pressure for now.